Becton, Dickinson and Company (BDX) Q1 2025 earnings summary

Executive summary

• Announced intent to separate Biosciences and Diagnostic Solutions, targeting completion in fiscal 2026, to create two focused, high-growth entities and unlock value.

• Q1 FY25 delivered strong results: revenue up 9.8% to $5.2B, adjusted EPS up 28% to $3.43, and significant margin expansion, driven by strong Medical segment growth and Advanced Patient Monitoring acquisition.

• Returned over $1 billion to shareholders in Q1 via dividends and a $750 million accelerated share buyback.

• Innovation pipeline advanced with regulatory clearances, new product launches, and expanded indications across multiple segments.

• Operational performance exceeded expectations, with margin expansion and strong execution of strategic initiatives.

Financial highlights

• Q1 revenue grew 9.8% year-over-year to $5.2B (9.6% currency-neutral, 3.9% organic), led by Medical segment growth and Advanced Patient Monitoring acquisition.

• Adjusted gross margin expanded 370 bps to 54.8%; adjusted operating margin up 340 bps to 23.6%.

• Adjusted diluted EPS rose 28% to $3.43, driven by operational strength and favorable tax items.

• Free cash flow was approximately $588–$600 million, with operating cash flow of $693 million.

• Cash and short-term investments at quarter-end were $711–$830 million; net leverage at 2.9x.

Outlook and guidance

• Affirmed full-year currency-neutral and organic revenue growth guidance; FY25 revenue expected at $21.7–$21.9 billion, with 4.0%–4.5% organic growth.

• Raised midpoint of adjusted diluted EPS guidance to $14.30–$14.60, up 10% at midpoint.

• Guidance incorporates $250 million FX headwind and China market decline.

• Adjusted effective tax rate expected between 14% and 15.25% for the year.

• More details on the planned separation to be provided by end of FY25, with completion targeted for FY26.